Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 593M 533M 498M 451M 847M 56.45B 852M 5.97B 2.33B 29.3B 2.23B 2.18B 94.23B P/E 2026 *
2.93x
P/E 2027 * 2.73x
Enterprise Value 593M 533M 498M 451M 847M 56.45B 852M 5.97B 2.33B 29.3B 2.23B 2.18B 94.23B EV / Sales 2026 *
1.26x
EV / Sales 2027 * 1.2x
Free-Float
96.76%
Yield 2026 *
-
Yield 2027 * -
1 day+0.28%
1 week-4.00%
Current month-9.32%
1 month-13.67%
3 months-9.55%
6 months-10.89%
Current year+6.82%
1 week 3.51
Extreme 3.51
3.96
1 month 3.51
Extreme 3.51
4.6
Current year 2.95
Extreme 2.95
5.78
1 year 1.43
Extreme 1.43
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 12/03/2021
Director of Finance/CFO 44 15/05/2026
Chief Tech/Sci/R&D Officer - 20/07/2026
Director TitleAgeSince
Director/Board Member 68 04/06/2021
Chairman 61 01/04/2019
Director/Board Member 56 01/04/2019
Date Insider Type Main position Quantity % Market Cap. Importance
9/15/26 A Free

Director

3,694 0.0022%
7/20/26 A Free

Chief Technology Officer

137,036 0.0832%
7/7/26 A Sell

Chief Financial Officer

-127,890 0.0777%
Change 5-day change 1-year change 3-year change Capi.($)
+0.28%-4.00%+143.24%-63.27% 593M
+3.62%+1.68%+48.80%+96.02% 1,040B
+2.13%-1.76%+33.04%+61.18% 599B
+3.32%+4.47%+23.72%+92.54% 485B
+3.80%+3.21%+73.99%+41.51% 350B
+3.09%+6.03%+27.85%+45.42% 345B
+2.82%+4.68%+17.38%+40.15% 272B
+3.40%+2.86%-3.33%+12.08% 244B
+3.21%+3.15%+45.01%+48.53% 223B
+3.80%+4.56%+29.59%+93.86% 183B
Average +2.51%+2.03%+43.93%+46.80% 374.34B
Weighted average by Cap. +2.91%+2.31%+36.61%+67.72%

Financials

2026 *2027 *
Net sales 471M 424M 396M 359M 673M 44.86B 677M 4.75B 1.85B 23.28B 1.77B 1.73B 74.89B 494M 444M 415M 376M 705M 47.02B 710M 4.97B 1.94B 24.4B 1.85B 1.81B 78.48B
Net income 203M 183M 171M 155M 290M 19.34B 292M 2.05B 799M 10.04B 763M 747M 32.29B 220M 198M 184M 167M 314M 20.92B 316M 2.21B 864M 10.86B 825M 808M 34.93B
Net Debt - -
Projected Income Statement - Annual - Ironwood Pharmaceuticals, Inc.
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
14/10/26 $3.600 +0.28% 1,222,151
13/10/26 $3.590 -4.52% 2,106,375
12/10/26 $3.760 -1.57% 1,035,818
09/10/26 $3.820 -1.29% 1,721,538
08/10/26 $3.870 +3.20% 2,403,997
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Ironwood Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.590USD
Average target price
6.100USD
Spread / Average Target
+69.92%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ironwood Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. IRWD Stock